Table 2 Antimicrobial activity of BMAP-27, BMAP-28, P19(9/B) and Tobramycin evaluated under different experimental conditions: “CF-like” (5% CO 2 , pH 6.8, SCFM) and “standard CLSI-recommended” (aerobiosis, pH 7.2, CAMHB)
Bacterial strains | Susceptibility (MICCF-like/MICCLSI) to: | |||
|---|---|---|---|---|
BMAP-27 | BMAP-28 | P19(9/B) | TOBRAMYCIN | |
P. aeruginosa | ||||
Pa1 | 8/4 | 8/8 | 4/16 | 4/0.25 |
Pa5 | 8/4 | 16/16 | 8/8 | 16/2 |
Pa6 | 8/8 | 16/16 | 16/8 | 8/8 |
Pa9 | 8/4 | 16/16 | 16/8 | 64/1 |
Sm109 | 4/8 | 4/16 | 4/8 | 128/64 |
Sm126 | 8/16 | 8/32 | 4/32 | 256/64 |
Sm143 | 8/8 | 4/8 | 4/4 | 8/2 |
S. aureus | ||||
Sa1 | 128/64 | 8/16 | 128/16 | 256/64 |
Sa3 | 64/64 | 4/32 | 64/16 | 256/16 |
Sa4 | 64/64 | 4/16 | 32/8 | 32/2 |
Sa7 | 64/16 | 4/16 | 64/8 | 256/2 |
Mean MIC CF-like /MIC CLSI | 1.5 | 0.5 | 2.8 | 23.9 |
P. aeruginosa | ||||
Pa1 | 8/8 | 8/16 | 16/32 | 4/1 |
Pa5 | 16/8 | 16/32 | 16/16 | 16/4 |
Pa6 | 16/8 | 16/16 | 16/32 | 8/8 |
Pa9 | 8/8 | 16/32 | 64/16 | 128/2 |
Sm109 | 8/16 | 8/16 | 8/8 | 256/128 |
Sm126 | 8/32 | 16/32 | 8/32 | 256/64 |
Sm143 | 16/8 | 8/8 | 4/4 | 8/8 |
Sa1 | 128/64 | 8/16 | 128/16 | 256/64 |
Sa3 | 64/64 | 4/32 | 64/16 | 256/32 |
Sa4 | 64/64 | 8/32 | 32/8 | 32/2 |
Sa7 | 64/NDa | 8/16 | 64/8 | 256/4 |
Mean MBC CF-like /MBC CLSI | 1.2 | 0.5 | 2.9 | 15.6 |